FDA Peptide Reclassification 2026: What's Actually Happened (And What Hasn't)

What Was Announced

On February 27, 2026, during Joe Rogan Experience Episode #2461, HHS Secretary Robert F. Kennedy Jr. made three key statements about peptides:

First, that his team had reviewed the FDA’s 2023 decision to place 19 peptides in Category 2 and determined the agency lacked the required safety signal to justify the restrictions. Under Section 503A of the FD&C Act, the FDA can restrict compounding when a substance presents a “significant safety risk.” Kennedy’s argument is that most of these peptides had been compounded for years without documented safety signals.

Second, that approximately 14 of the 19 restricted peptides would be moved back to Category 1 — meaning licensed compounding pharmacies could legally prepare them again with a valid physician prescription.

Third, that this would happen “within a couple of weeks.”

The “couple of weeks” turned into roughly seven, and the “14 back to Category 1” turned into “12 off Category 2” — a meaningfully different thing, as we explain below.

What Has Actually Happened

April 15, 2026 — the FDA acted. The agency republished its interim lists of bulk drug substances for 503A compounding and announced its intent to remove 12 peptides from Category 2, the “do not compound” list. The removals took effect roughly a week later. In most cases the mechanism was procedural: the parties who originally nominated these substances withdrew their nominations, so the FDA moved them off the significant-safety-concern list.

Two corrections to the February announcement matter here:

• The count was 12, not 14. RFK Jr.’s “~14 of 19” was a verbal target on a podcast, not a regulatory action.
• The peptides were removed from Category 2 — they were not placed into Category 1. They were never in Category 1 to begin with. Removal from the prohibited list is not the same as authorization to compound.

The 12 peptides removed from Category 2: BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, MOTS-c, Emideltide (DSIP), Semax, Epitalon, Cathelicidin (LL-37), GHK-Cu (injectable routes), Melanotan II, PEG-MGF, and Dihexa acetate.

What comes next — the July 23–24 PCAC meeting. To become lawfully compoundable under 503A, a substance has to be added to the 503A Bulk Drug Substances List. That requires review by the FDA’s Pharmacy Compounding Advisory Committee (PCAC), an FDA determination, and formal notice-and-comment rulemaking. The FDA has scheduled a PCAC meeting for July 23–24, 2026 (docket FDA-2025-N-6895) to review seven of the twelve: BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide/DSIP, Semax, and Epitalon on July 24. The remaining five are expected at a later meeting before the end of February 2027.

Even a favorable PCAC vote is only a recommendation. The committee advises; the FDA decides; rulemaking follows. Regulatory counsel tracking this expect final rulemaking to be more than a year away. So the peptides that came off Category 2 in April are, as of July, in a legal in-between — not prohibited, not yet permitted for compounding.

What Removal From Category 2 Does and Doesn’t Do

What it does: it lifts the explicit “do not compound” prohibition on these 12 substances, and it starts the clock on the process that could eventually make them compoundable.

What it does NOT do: it does not add them to the 503A list, does not make it lawful for a pharmacy to compound them today, does not make them FDA-approved drugs, does not demonstrate safety or efficacy, and does not make them available over the counter. The evidence gaps PeptideExaminer has documented in every peptide profile are unchanged — the FDA’s own staff scientists, in their July-meeting briefing documents, concluded the human evidence for BPC-157 and TB-500 is insufficient.

What this is NOT: FDA approval. OTC access. Scientific validation. Proof that these peptides work. A green light to buy from grey-market vendors.

The Two Review Waves

The 12 peptides removed from Category 2 are being reviewed in two batches.

Wave 1 — PCAC review July 23–24, 2026 (7 peptides):

Peptide	Primary Research Area	Human Clinical Data
BPC-157	Tissue repair, gut healing	One small, poorly documented trial (per FDA staff review)
KPV	Anti-inflammatory, gut	Zero human trials
TB-500 (Tβ4 fragment)	Wound healing, recovery	Zero human studies (per FDA staff review)
MOTS-c	Mitochondrial, metabolic	Very limited
Emideltide (DSIP)	Sleep regulation	Limited, dated
Semax	Nootropic, cognitive	Russian clinical use; not to Western regulatory standard
Epitalon	Telomerase / “longevity” claims	Minimal

Wave 2 — expected at a later PCAC meeting before end of February 2027 (5 peptides):

Peptide	Primary Research Area
Cathelicidin (LL-37)	Antimicrobial
GHK-Cu (injectable routes)	Anti-aging, wound healing
Melanotan II	Tanning, libido
PEG-MGF	Muscle growth
Dihexa acetate	Cognitive

Which Peptides Stayed Restricted

Here we’re going to be honest about the limits of what’s confirmed. Clinic and vendor sites have circulated tidy “these five stayed restricted” lists (commonly naming Melanotan II, LL-37, PEG-MGF, GHRP-2, and MK-677) — but at least three of those (Melanotan II, LL-37, PEG-MGF) were in fact among the 12 removed from Category 2, just deferred to the Wave 2 review. Those lists are wrong.

Peptides that were not among the 12 — such as GHRP-2, GHRP-6, and MK-677 (which PCAC voted against compounding back in December 2024) — presumably remain restricted. But we have not located a primary FDA document that enumerates exactly what stayed in Category 2, so we’re not going to publish a definitive “still-restricted” list we can’t source. When the FDA posts an updated interim list that settles it, we’ll cite it here.

Separately, several peptides tied to ongoing litigation — including AOD-9604, CJC-1295, ipamorelin, and Thymosin Alpha-1 — are on their own legal track and were not part of the 12-peptide April action.

The Grey Market Question

Kennedy explicitly acknowledged on the podcast that the Category 2 restrictions “created the grey market.” The logic is straightforward: when regulated compounding was banned, demand didn’t disappear — it moved to unregulated channels. Chinese peptide imports to the US roughly doubled to $328 million in the first three quarters of 2025.

The reclassification argument positions regulated compounding as the harm-reduction alternative to unregulated imports. This is a defensible public health argument. But it’s important to understand what reclassification does and doesn’t do to the grey market:

It creates a legal alternative — physician prescription + compounding pharmacy provides a regulated pathway that didn’t exist under Category 2.

It does not validate the grey market — grey-market vendors selling “research use only” peptides remain in the same legal position regardless of reclassification. The Intended Use Doctrine, ITC exclusion orders, and the SAFE Drugs Act all target the grey-market model independently of compounding eligibility.

It may accelerate grey-market decline — when a legal pathway exists, the justification for buying unregulated products weakens. This is already happening: Peptide Sciences shut down March 6, Amino Asylum was raided in June 2025, and 7+ vendors closed in 2025. Enforcement against grey-market sellers has continued right through the reclassification — including a wave of “research use only” warning letters dated March 31, 2026 and roughly 25 telehealth GLP-1 letters in June.

What to Do Right Now

Do not assume you can buy or compound these peptides legally yet. Removal from Category 2 did not make BPC-157, TB-500, or the others compoundable. That waits on the PCAC review and a rulemaking process that’s likely more than a year out. A pharmacy compounding these substances today is still taking regulatory risk.

Do not buy from grey-market vendors on the strength of the reclassification. It didn’t change grey-market legality at all — the “research use only” model remains squarely in the FDA’s enforcement sights, as the spring’s warning letters show.

Find a physician who understands peptide therapy. If and when the rulemaking opens a compounding pathway, you’ll need a prescription from a licensed provider. Establishing that relationship now means you’ll be ready.

Be skeptical of clinic websites claiming peptides are “legal again” or “back in Category 1.” Both framings are wrong. The peptides came off Category 2; they are not in Category 1, and they are not lawfully compoundable today. Ask a site making those claims to show you where the FDA added these substances to the 503A list. They can’t, because it hasn’t happened.

Watch the July 23–24 PCAC meeting — and who’s on the panel. As independent reporting has documented, the advisory slate seated for this review includes members with direct financial stakes in peptides, while the FDA’s own scientists concluded the evidence is insufficient. Read the coverage accordingly.

Read the actual evidence for any peptide you’re considering. Reclassification doesn’t change the science. Our peptide profiles provide evidence-rated assessments of what published research actually shows for each compound — not what influencers or clinics claim.

PeptideExaminer Will Keep Updating This Page

This page was first published March 28, 2026, when no formal FDA action had occurred, and updated July 6, 2026 to reflect the April 15 Category 2 removals and the pending PCAC review. We’ll update it again after the July 23–24 meeting with:

• The committee’s recommendation on each of the seven peptides
• Analysis of how the panel weighed the FDA staff scientists’ concerns
• The FDA’s response and any move toward rulemaking
• Updated regulatory status in every affected peptide profile
• Assessment of implications for the grey market

Bookmark this page. We’ll have the independent analysis when it matters.

---

PeptideExaminer — We don’t sell peptides. We tell you the truth about them.